Related Experiment Video
Updated: Feb 10, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
[Dyslipidemia and hypertension - what to worry about more?]
Insights
Nearly half of patients with arterial hypertension also have dyslipidemia. Combined treatment for both conditions, especially with fixed drug combinations, significantly reduces cardiovascular events and mortality.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Dyslipidemia affects approximately 50% of patients with arterial hypertension.
- Elevated blood pressure and cholesterol levels are directly proportional to cardiovascular event risk.
Purpose of the Study:
- To highlight the significant impact of dyslipidemia on cardiovascular risk in hypertensive patients.
- To emphasize the benefits of combined treatment for hypertension and dyslipidemia.
- To explore the role of fixed drug combinations in improving treatment adherence and efficacy.
Main Methods:
- Review of existing literature on the co-occurrence of arterial hypertension and dyslipidemia.
- Analysis of cardiovascular event rates in patients treated for one or both conditions.
- Evaluation of the impact of fixed-dose drug combinations on patient adherence and outcomes.
Main Results:
- Treatment of dyslipidemia shows a greater reduction in cardiovascular mortality than hypertension treatment alone.
- Concurrent treatment of both conditions yields significantly better outcomes than monotherapy.
- Fixed drug combinations enhance adherence and improve the efficacy of combined therapy.
Conclusions:
- Managing dyslipidemia is crucial in patients with arterial hypertension.
- Combined pharmacotherapy for hypertension and dyslipidemia is superior to monotherapy.
- Fixed drug combinations represent an effective strategy to improve adherence and reduce cardiovascular events.
Abstract:
Dyslipidemia is present in every other patient with arterial hypertension. With increasing blood pressure and cholesterol levels, the risk of cardiovascular events increases proportionally. Treatment of dyslipidemia appears to lower cardiovascular mortality to a greater extent than treatment of hypertension. A significant proportion of patients with dyslipidemia indicated for drug therapy are not treated at all or treated insufficiently and do not reach the target values. Concurrent treatment of hypertension and dyslipidemia reduces the incidence of cardiovascular events significantly more than treating only one of these diseases. An even better efficacy of combined treatment of hypertension and dyslipidemia can be achieved by improving patient adherence using fixed drug combinations.Key words: arterial hypertension - cardiovascular events - dyslipidemia - fixed combinations -treatment.
Related Concept Videos
Hypertension I: Introduction
Hypertension II: Pathophysiology
Hypertension V: Nursing Management
Hypertension and Regulation of Blood Pressure
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
Hypertension III: Clinical Manifestations and Diagnostic Studies

